Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Secondary, safety and negative control endpoints For individual components of the primary endpoint, semaglutide versus sitagliptin reduced myocardial infarction (HR 0.81, 95% CI 0.70 to 0.92) and stroke (HR 0.84, 95% CI 0.71 to 0.99) in the expanded populations at low, moderate and high cardiovascular risk
Acknowledgements This work is supported by the NSF-CREST Grant number HRD 1036494 and HRD 1547771, and NSF-IGERT
Individuals Already Using GLP-1 Medications Want to track progress independently Avoid repeated clinic visits 2
Both trials enrolled predominantly high-risk populations81% of LEADER and 83% of SUSTAIN-6 participants had established cardiovascular disease [3]
US$ 21.30
US$ 22.30
US$ 21.81
US$ 24.03
